Susan Dana Jones
Chief Technology Officer · Tourmaline Bio, Inc.
- 2025
- Oct 28, 2025
- 1
Summary
Latest filing:
Susan Dana Jones is Chief Technology Officer of Tourmaline Bio, Inc. (TRML). 1 SEC Form 4 filing on record, dated 28 October 2025.
Recent transactions
2The latest 2 SEC Form 4 transactions reported by Susan Dana Jones.
Trading pattern
InsiderAlpha's records for Susan Dana Jones go back to 2025: 1 primary Form 4 filing, an average of 0.5 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same sector
No other insider has filed at Susan Dana Jones's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- ULSE Inc. - $146.25M in ULS purchases and sales in the last 12 months
- Matthew Rabinowitz - $139.55M in NTRA purchases and sales in the last 12 months
- BAIN CAPITAL INVESTORS LLC - $134.38M in KLRA purchases and sales in the last 12 months
- Andrew T. Kaplan - $134.38M in KLRA purchases and sales in the last 12 months
- Fairmount Funds Management LLC - $133.53M in APGE purchases and sales in the last 12 months
- Stephen M. Bloch - $125.05M in LQDA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Susan Dana Jones?
Susan Dana Jones is a corporate insider, tracked as Chief Technology Officer of Tourmaline Bio, Inc. (TRML). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Susan Dana Jones last file a Form 4?
The only primary Form 4 on record is dated 28 October 2025.